The stock will trade on the GFORCE-1 MRT-8102 data readout expected in H2 2026, which is the next major binary catalyst. Monitor for the first patient visit milestone payment from Novartis for the MRT-6160 Phase 2 study, which would trigger a milestone payment. The $626M cash runway into 2029 removes near-term financing risk but the widening operating losses and declining collaboration revenue are consistent with a pre-commercial biotech.
Price Chart
Executive Summary
Monte Rosa Therapeutics reported Q2 2026 results with collaboration revenue of $9.0M (down 61% YoY from $23.2M) and a net loss of $43.4M, widening from a $12.3M loss in Q2 2025. The company highlighted strong pipeline execution with two Phase 2 trials activated (MRT-2359 in mCRPC and MRT-6160 in Sjögren's disease), completed enrollment for the GFORCE-1 study of MRT-8102 with data readout expected in H2 2026, and a cash runway into 2029 with $626M in cash and securities. The revenue decline and widening losses are typical for a clinical-stage biotech advancing programs, while the operational milestones represent meaningful pipeline progress but remain binary catalysts with no approved products yet.
Key Financial Metrics
Key Facts
- Collaboration revenue for Q2 2026 was $9.0M, down from $23.2M in Q2 2025
- Net loss widened to $43.4M from $12.3M in Q2 2025
- Cash, cash equivalents, restricted cash, and marketable securities of $626.0M as of June 30, 2026, expected to fund operations into 2029
- Enrollment and dosing completed for GFORCE-1 Phase 1 study of MRT-8102 in elevated CVD risk; readout anticipated H2 2026
- Novartis activated a Phase 2a/b study of MRT-6160 (DDY391) in Sjögren's disease
- MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC with AR mutations activated
- R&D expenses increased to $48.0M from $30.7M in Q2 2025, driven by MRT-8102 program spending
- Shares outstanding increased to 85,226,427 as of June 30, 2026, from 65,543,723 at December 31, 2025, reflecting the January 2026 $345M public offering
Financial Impact
Net loss of $43.4M in Q2 2026 vs $12.3M loss in Q2 2025; collaboration revenue declined $14.2M YoY; cash burn of $45.2M in Q2 2026
Risk Factors
- Clinical trial failure risk for MRT-8102 GFORCE-1 readout in H2 2026
- Dependence on collaboration revenue from Roche and Novartis, which declined significantly YoY
- No approved products or commercial revenue; entirely dependent on pipeline execution
- Dilution from January 2026 offering increased share count by 30%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336681 |
| Document: glue-20260806.htm | 0001193125-26-336681 |
| Document: 0001193125-26-336681-index-headers.html | 0001193125-26-336681 |
| Document: 0001193125-26-336681-index.html | 0001193125-26-336681 |
| Document: 0001193125-26-336681.txt | 0001193125-26-336681 |
| 8-K Data (Synthetic) | 0001193125-26-336681 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 8-K | $11.26 | awaiting T+60 | — | $10.41 (−7.55%) |
Sep 30, 2026 25d ago | Press Release | $11.26 | awaiting T+60 | — | $10.41 (−7.55%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.41 (−33.74%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.41 (−55.66%) |
Jul 7, 2026 15w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.41 (−56.73%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.41 (−57.00%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.41 (−57.00%) |
Jun 29, 2026 16w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.41 (−56.98%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.41 (−53.30%) |
Jun 2, 2026 20w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.41 (−40.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers